The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Coffee Consumption, Gender, and Parkinson’s Disease Mortality in the Cancer Prevention Study II Cohort: The Modifying Effects of Estrogen
Abstract
Caffeine consumption is associated with a reduced risk of Parkinson's disease in men but not in women. This gender difference may be due to an interaction between caffeine and use of postmenopausal estrogens. The authors prospectively assessed the relation between coffee consumption and Parkinson's disease mortality among participants in the Cancer Prevention Study II, a cohort of over 1 million people enrolled in 1982. Causes of deaths were ascertained through death certificates from January 1, 1989, through 1998. Parkinson's disease was listed as a cause of death in 909 men and 340 women. After adjustment for age, smoking, and alcohol intake, coffee consumption was inversely associated with Parkinson's disease mortality in men (p(trend) = 0.01) but not in women (p = 0.6). In women, this association was dependent on postmenopausal estrogen use; the relative risk for women drinking 4 or more cups (600 ml) of coffee per day compared with nondrinkers was 0.47 (95% confidence interval: 0.27, 0.80; p = 0.006) among never users and 1.31 (95% confidence interval: 0.75, 2.30; p = 0.34) among users. These results suggest that caffeine reduces the risk of Parkinson's disease but that this hypothetical beneficial effect may be prevented by use of estrogen replacement therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An inverse association between coffee consumption and PD risk has been found in several epidemiological studies [110,121,122,123].”
From Effect of Caffeine Consumption on the Risk for Neurological and Psychiatric Disorders: Sex Differences in Human (2020) · cites this paper as [122]
Citations
Cites
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 876
A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease
Hernán, M. A., Takkouche, B., Caamaño‐Isorna, F., & Gestal‐Otero, J. J. (2002) · Annals of Neurology · doi:10.1002/ana.10277 · Cited by 818
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677
Self-citationAdenosine, Adenosine Receptors and the Actions of Caffeine
Fredholm, B. B. (1995) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1995.tb00111.x · Cited by 597
Calle, E. E., & Terrell, D. D. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116664 · Cited by 342
Neuroprotective agents for clinical trials in Parkinson’s disease
Ravina, B. M., Fagan, S. C., Hart, R. G., Hovinga, C. A., Murphy, D. D., Dawson, T. M., & Marler, J. R. (2003) · Neurology · doi:10.1212/01.wnl.0000058760.13152.1a · Cited by 262
Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease
Ascherio, A., Chen, H., Schwarzschild, M. A., Zhang, S. M., Colditz, G. A., & Speizer, F. E. (2003) · Neurology · doi:10.1212/01.wnl.0000046523.05125.87 · Cited by 237
Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: A case-control study
Benedetti, M. D., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2000) · Neurology · doi:10.1212/wnl.55.9.1350 · Cited by 234
Benedetti, M. D., Maraganore, D. M., Bower, J. H., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2001) · Movement Disorders · doi:10.1002/mds.1170 · Cited by 224
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–232 of 232
Beverages, caffeine, and Parkinson's disease
Alstadhaug, K. B., Tzoulis, C., & Simonsen, A. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89834-8.00011-8 · Cited by 1
Natural Compound Toxicity: An Egregiously Overlooked Topic
Bhardwaj, P., Aiman, A., Iram, F., Saifi, I., Basir, S. F., Hassan, M. I., Islam, A., & Manzoor, N. (2024) · Springer eBooks · doi:10.1007/978-981-97-5165-5_25 · Cited by 2
Genetic-based diagnostics of Parkinson’s disease and other Parkinsonian syndromes
Somerville, E. N., & Gan‐Or, Z. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2427625 · Cited by 1
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists
Simola, N., Pinna, A., Frau, L., & Morelli, M. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_103 · Cited by 1
Clinical Disease Progression in Parkinson’s Disease
Alves, G. W. (2006) · Cited by 1
The role of beverages in a healthy diet: key issues and guidelines
Popkin, B. M., Bray, G. M., Caballero, B. H., Frei, B. B., & Willett, W. C. (2009) · Elsevier eBooks · doi:10.1533/9781845695569.4.451 · Cited by 1
Parkinson’s Disease, Lithium and Stem Cells
Burckhalter, L., & Gallicchio, V. S. (2019) · Journal of Clinical and Laboratory Medicine · doi:10.16966/2572-9578.126 · Cited by 1
The Putative Neuroprotective Effects of Caffeine
James, M. J. E., Chen, P. X., Morelli, M., Postuma, R., & Schwarzschild, M. A. (2011) · Journal of Caffeine Research · doi:10.1089/jcr.2011.1207 · Cited by 1
Harris, M. (2010) · cIRcle (University of British Columbia) · doi:10.14288/1.0071498 · Cited by 1
Current Concepts on the Etiology and Pathogenesis of Parkinson Disease
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50008-5 · Cited by 1
Margarida, D., Moreira, A., De, E., Biológicas, P., Aplicações, E., Extratos, D., Partir, O. A., Agro-industriais, D. S., Margarida, D., & Moreira, A. (2014)
Caffeine Reduces Risk of Parkinson’s Disease
Harnprasertpongse, N., & Sangdee, C. (2014) · Journal of Basic and Applied Pharmacology
Nolan, B. (2009) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t3ks6rs0
Coffee and Cirrhosis: Active Ingredients?—Reply
Klatsky, A. L., Morton, C. C., Udaltsova, N. V., & FRIEDMAN, G. D. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.21.2405-a
Ensuring good nutritional status in patients with Parkinson's disease: challenges and solutions
Baroni, L., & Zuliani, C. (2014) · Journal of Parkinsonism and Restless Legs Syndrome · doi:10.2147/jprls.s49186
Kaffee gegen Morbus Parkinson?
Stark, H. (2006) · Pharmazie in unserer Zeit · doi:10.1002/pauz.200690057
FP, C. D. P. (2014) · Journal of Nutrition & Food Sciences · doi:10.4172/2155-9600.1000313
L-dopa and the serotonergic system
Stansley, B. J. (2015) · OhioLink ETD Center (Ohio Library and Information Network)
ENVIRONMENTAL PERSPECTIVES ENVIRONMENTAL PERSPECTIVES
Bronstein, J. M., Carvey, P. M., Chen, H., Cory‐Slechta, D. A., Monte, D. A. D., Duda, J. E., English, P. B., Goldman, S. M., Grate, S. J., Hansen, J., et al. (2008)
The Potential of Caffeine for the Inhibition of Cognitive Decline in the Aged
Harris, G. K., & Summers, C. R. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374228-5.00020-2
Diagnosis and Neuroprotection in Parkinson's Disease
Müller, T. H. (2007) · Springer eBooks · doi:10.1007/978-0-387-30377-2_2
Reactive dopamine metabolites and neurotoxicity
Vanle, B., Doorn, J. A., Duffel, M. W., Quinn, D. M., Roman, D. L., & Kerns, R. J. (2016) · doi:10.17077/etd.28c5nhya
Cai, X. (2020) · Digital Repository Service (Northeastern University) · doi:10.17760/d20398331
Lo, R. Y., & Tanner, C. M. (2013) · Neurological disease and therapy · doi:10.1201/b14361-3
Ludwig, I. A., Clifford, M. N., Lean, M. E. J., & Crozier, A. (2016) · Nutraceutical science and technology · doi:10.1201/b19490-57
Vanderlei, L. C. A. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2022.tde-03012023-123841
Instituto de pesquisa café e saúde: Prevenção de doenças e melhora da qualidade de vida
Cunha, R. A., Rohden, F., & Souza, D. O. (2024) · Research Society and Development · doi:10.33448/rsd-v13i5.45666
Coffee and Parkinson’s Disease
Śmiłowska, K., Szejko, N., & Carvalho, V. (2025) · Springer eBooks · doi:10.1007/978-3-031-93459-9_27
Exploring the Causal Links Between 338 Cerebrospinal Fluid Metabolites and Parkinson's Disease
Zhang, H., Li, C., Yu, J., Liang, Y., Wu, Y., & Cao, F. (2025) · Brain and Behavior · doi:10.1002/brb3.70815
Functional Networks in Parkinson’s Disease
Jha, A. (2013) · UCL Discovery (University College London)
Metadata
- Authors
- Ascherio, A.
- Affiliations
- Harvard University (US)
- Corresponding author
- Ascherio, A.
- ORCID
- Ascherio, A.
- Venue
- American Journal of Epidemiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-11-15
- Volume
- 160
- Issue
- 10
- Pages
- 977-984
- ISSN
- 0002-9262 (ISSN-L)
- OpenAlex
- W2113279750
- Cited by
- 232
- References
- 20
- Citations by year
- 2025: 6 · 2024: 6 · 2023: 8 · 2022: 13 · 2021: 7 · 2020: 6 · 2019: 12 · 2018: 15 · 2017: 16 · 2016: 9 · 2015: 14 · 2014: 18 · 2013: 14 · 2012: 9
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Epidemiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- Kinetics Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (NS045893-01, R01NS045893)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- coffee consumption, caffeine, estrogen replacement therapy, postmenopausal hormone use, sex differences, Cancer Prevention Study II
- MeSH terms
- Aged, Coffee, Drug Interactions, Estrogens, Female, Humans, Male, Middle Aged, Neoplasms, Parity, Parkinson Disease, Surveys and Questionnaires, Risk, Sex Factors, Smoking, United States, Confidence Intervals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
